2024 July PLA Codes Arrive

2024 July PLA Codes Arrive

The Quarterly Update for Clinical Laboratory Fee Schedule (CLFS) and Laboratory Services Subject to Reasonable Charge Payment contains a new series of PLA codes that are effective July 1, 2024. The following table contains the codes and long descriptors. Notify your staff of these updates. For a full list of the codes and other info on the Update, please review the transmittal link.

Table 1 PLA Codes
CPT CodeLong DescriptorTOS
0450U  Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LCMS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides  5
  0451UOncology (multiple myeloma), LCMS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundanc  5
0452U  Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylationspecific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer    5
0453UOncology (colorectal cancer), cellfree DNA (cfDNA), methylationbased quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)5
0454URare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping5
0455UInfectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected5
0456UAutoimmune (rheumatoid arthritis), next-generation sequencing (NGS), gene expression testing of 19 genes, whole blood, with analysis of anticyclic citrullinated peptides (CCP) levels, combined with sex, patient global assessment, and body mass index (BMI), algorithm reported as a score that predicts nonresponse to tumor necrosis factor inhibitor (TNFi) therapy5
0457UPerfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative5
0458UOncology (breast cancer), S100A8 and S100A9, by enzymelinked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score5 4
0459Uβ-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology5
Coding Continues to Evolve, Don’t Underestimate the Future Challenges…

Stay ahead of regulatory changes with the “2024 Lab Regulatory Update: Preparing for the Future.” This comprehensive resource is designed to equip your lab with the latest compliance strategies and insights. Don’t let new regulations catch you off guard—ensure your lab’s readiness and compliance today. Learn more and secure your copy to stay informed and prepared.

An Exclusive Offer Just for You:

Maximize your earnings in the remaining 6 months of 2024 by seizing our 2024 close-out opportunity and securing your financial future with our Coding Essentials for Laboratories. Order your resource today and enjoy 50% savings while enhancing your coding and billing expertise. This exclusive offer is valid until July 5th, and inventory is limited.

To receive your 50% discount, use the code CO5024 at checkout on our web store.

Act now before this exclusive offer expires on July 5th!

Information Source:


Print Friendly, PDF & Email

You May Also Like

Leave a Reply

Please log in to your account to comment on this article.


Subscribe to receive our News, Insights, and Compliance Question of the Week articles delivered right to your inbox.

Resources You May Like

Trending News

Unlock 50% off all 2024 edition books when you order by July 5! Use the coupon code CO5024 at checkout to claim this offer!